Treatment of Hepatitis C Virus in HIV/ HCV Co-Infection
Journal: Journal of Hepatitis Research (Vol.2, No. 2)Publication Date: 2015-06-24
Authors : Iacob SA; Iacob DG;
Page : 1-6
Keywords : Hepatitis C virus; HIV infection; Antiretroviral therapy; Direct acting antivirals;
Abstract
Around 5-10 million people present HIV/ HCV co-infection. The treatment regimen currently recommended in this population is based on pegylated interferon and ribavirin, with a success rate below 30% and multiple side effects. Various clinical trials have also explored different interferon free regimens in patients with HIV/HCV co-infection, proving that Direct Acting Antivirals (DAAs) can induce a sustained viral response over 95%. Moreover co-infected HIV/ HCV patients receiving HCV treatment could further benefit from HCV clearance as this allows the preservation of liver function, attenuates the harm effect of multiple hepatotoxic therapies and lowers the risk of hepatocellular carcinoma. Nevertheless, the administration of DAAs in HIV patients requires careful monitoring and treatment considerations on various issues such as variable adherence in some categories of patients, insufficient drug interactions or the high cost of therapy. The current article is an overview of the currently antiviral C hepatitis drugs studied in HIV/ HCV co-infected individuals.
Other Latest Articles
- Chronic Hepatitis C in the Elderly: A New Challenge
- The Readiness Rate of Couples Referred To the Premarital Counseling Center for Hepatitis B Virus Infection Testing in Yazd-Iran (2012)
- THE CONCEPT OF THE INTERNAL PICTURE OF HEALTH
- Undiagnosed Vertically Acquired HCV Infection Leading to Hepatocellular Carcinoma and Liver Transplant in an Adolescent Female: A Case Report
- TÜRK KAĞANLIĞI VE TÜRK BENGÜ TAŞLARI ÜZERİNE YENİ BİR ESER (A NEW WORK ABOUT TURKISH KHAGHANESE AND TURKISH ETERNAL INSCRIPTION)
Last modified: 2017-03-28 19:26:03